Spots Global Cancer Trial Database for Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
Official Title: A Phase 1 Study of TRAIL-DR5 Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Study ID: NCT02983006
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety profile, tolerability, and immunoregulatory (pharmacodynamic; PD) activity of DS-8273a administered in combination with nivolumab (anti-PD-1 antibody) to subjects with unresectable Stage III or Stage IV melanoma.
Detailed Description: Principal investigator hypothesize that TRAIL D5 antibody DS-8273a administered in combination with nivolumab will be well tolerated and that the addition of DS-8273a will augment the clinical efficacy of nivolumab.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
Contact Details
Name: Jeffrey Weber, MD, PhD
Affiliation: NYU Perlmutter Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
